Aptose Biosciences’ (APTO) Buy Rating Reaffirmed at Canaccord Genuity
Canaccord Genuity reaffirmed their buy rating on shares of Aptose Biosciences Inc. (NASDAQ:APTO) in a research note issued to investors on Saturday morning. They currently have a $7.00 target price on the stock.
Several other research firms have also commented on APTO. Zacks Investment Research raised shares of Aptose Biosciences from a sell rating to a hold rating in a report on Tuesday. RBC Capital Markets reaffirmed an outperform rating on shares of Aptose Biosciences in a report on Tuesday, September 13th. Finally, Royal Bank Of Canada reaffirmed an outperform rating and issued a $23.00 price target on shares of Aptose Biosciences in a report on Saturday, June 25th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $12.30.
Shares of Aptose Biosciences (NASDAQ:APTO) opened at 2.40 on Friday. The company’s market capitalization is $30.94 million. Aptose Biosciences has a one year low of $1.92 and a one year high of $6.40. The stock has a 50 day moving average price of $2.22 and a 200 day moving average price of $2.47.
An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors own 19.47% of the company’s stock.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.